logo

Conatus Pharmaceuticals Inc (CNAT)



Trade CNAT now with
  Date
  Headline
9/23/2015 4:01:26 PM Conatus Pharmaceuticals Trading Halted; Pending News
8/5/2015 5:42:09 PM Conatus Pharmaceuticals Posts Q2 Loss/share Of $0.31 Vs. Loss $0.34 Year Ago
5/7/2015 4:53:18 PM Conatus Pharma Posts Q1 Loss Per Share Of $0.38 Vs. Loss $0.34 Year Ago
4/2/2015 9:07:37 AM Conatus Prices Public Offering Of 3.50 Mln Shares At $5.75 Per Share
4/1/2015 4:10:25 PM Conatus Pharma Announces Proposed Public Offering Of Common Stock
3/26/2015 7:09:16 AM Conatus Reports Successful Top-Line Results From NAFLD/NASH Clinical Trial Of Emricasan
3/11/2015 4:04:59 PM Conatus Pharmaceuticals Q4 Loss Per Share $0.34 Vs. $0.33 Last Year
1/8/2015 4:11:41 PM Conatus Pharmaceuticals, Trading Expected To Resume At 4:30 PM ET.
1/5/2015 7:03:36 AM Conatus To Report Top-line Results From ACLF And Organ Impairment Clinical Trials Of Emricasan
11/12/2014 4:29:38 PM Conatus Pharma Q3 Loss Per Share $0.42 Vs Loss $0.28 Last Year
10/1/2014 4:02:02 PM Conatus Pharmaceuticals Appoints David Hagerty As EVP, Clinical Development
9/2/2014 7:02:46 AM Conatus Pharma Begins Phase 2 Trial In Patients With Liver Cirrhosis
  
 
>